131 related articles for article (PubMed ID: 23131146)
1. Chemosensitivity and p53; new tricks by an old dog.
Lønning PE; Knappskog S
Breast Cancer Res; 2012 Nov; 14(6):325. PubMed ID: 23131146
[TBL] [Abstract][Full Text] [Related]
2. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
[TBL] [Abstract][Full Text] [Related]
3. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
[TBL] [Abstract][Full Text] [Related]
4. Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.
Knappskog S; Berge EO; Chrisanthar R; Geisler S; Staalesen V; Leirvaag B; Yndestad S; de Faveri E; Karlsen BO; Wedge DC; Akslen LA; Lilleng PK; Løkkevik E; Lundgren S; Østenstad B; Risberg T; Mjaaland I; Aas T; Lønning PE
Mol Oncol; 2015 Oct; 9(8):1553-64. PubMed ID: 26004085
[TBL] [Abstract][Full Text] [Related]
5. Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.
Yndestad S; Austreid E; Svanberg IR; Knappskog S; Lønning PE; Eikesdal HP
Oncotarget; 2017 Jun; 8(25):41227-41241. PubMed ID: 28476032
[TBL] [Abstract][Full Text] [Related]
6. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
7. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Østenstad B; Lundgren S; Berge EO; Risberg T; Mjaaland I; Maehle L; Engebretsen LF; Lillehaug JR; Lønning PE
PLoS One; 2008 Aug; 3(8):e3062. PubMed ID: 18725978
[TBL] [Abstract][Full Text] [Related]
8. Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.
Wiegmans AP; Saunus JM; Ham S; Lobb R; Kutasovic JR; Dalley AJ; Miranda M; Atkinson C; Foliaki ST; Ferguson K; Niland C; Johnstone CN; Lewis V; Collins SJ; Lakhani SR; Al-Ejeh F; Möller A
JCI Insight; 2019 Feb; 5(6):. PubMed ID: 30830863
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
Lehmann-Che J; André F; Desmedt C; Mazouni C; Giacchetti S; Turpin E; Espié M; Plassa LF; Marty M; Bertheau P; Sotiriou C; Piccart M; Symmans WF; Pusztai L; de Thé H
Oncologist; 2010; 15(3):246-52. PubMed ID: 20228131
[TBL] [Abstract][Full Text] [Related]
10. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts.
Kim TH; Kim HS; Kang YJ; Yoon S; Lee J; Choi WS; Jung JH; Kim HS
Biochim Biophys Acta; 2015 Feb; 1850(2):401-10. PubMed ID: 25445714
[TBL] [Abstract][Full Text] [Related]
11. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
12. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
Cuddihy AR; Jalali F; Coackley C; Bristow RG
Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
[TBL] [Abstract][Full Text] [Related]
13. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.
Aas T; Børresen AL; Geisler S; Smith-Sørensen B; Johnsen H; Varhaug JE; Akslen LA; Lønning PE
Nat Med; 1996 Jul; 2(7):811-4. PubMed ID: 8673929
[TBL] [Abstract][Full Text] [Related]
14. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.
Jackson JG; Pant V; Li Q; Chang LL; Quintás-Cardama A; Garza D; Tavana O; Yang P; Manshouri T; Li Y; El-Naggar AK; Lozano G
Cancer Cell; 2012 Jun; 21(6):793-806. PubMed ID: 22698404
[TBL] [Abstract][Full Text] [Related]
15. TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.
Wang Y; Xu Y; Chen J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2016 Jan; 138(2):489-96. PubMed ID: 26238069
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells.
Tsou SH; Hou MH; Hsu LC; Chen TM; Chen YH
Int J Mol Med; 2016 Jan; 37(1):233-42. PubMed ID: 26572087
[TBL] [Abstract][Full Text] [Related]
17. Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center.
Khallaf SM; Roshdy J; Ibrahim A
J Egypt Natl Canc Inst; 2020 Apr; 32(1):20. PubMed ID: 32372114
[TBL] [Abstract][Full Text] [Related]
18. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
19. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
[TBL] [Abstract][Full Text] [Related]
20. Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations.
Fimognari C; Nüsse M; Lenzi M; Sciuscio D; Cantelli-Forti G; Hrelia P
Mutat Res; 2006 Oct; 601(1-2):92-101. PubMed ID: 16843502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
